Open AccessJournal Article
Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
12
TL;DR: Measurements of Trop I levels after Anthracyclines can be useful in detecting early cardiotoxicity and tailoring further therapy in patients with early Breast cancer.
read more
Abstract: Background: Anthracyclines are one of the most effective chemotherapeutic agents in management of Breast cancer, however Anthracycline induced cardiotoxicity remains a matter of special concern Detection of early toxicity by use of biomarkers like Troponins has been the focus of interest in recent years We measured Troponin I levels after chemotherapy with anthracyclines and correlated it with ECG, Echocardiography and clinical findings Methods: Patients with early Breast cancer eligible for chemotherapy were included in the study All patients underwent clinical evaluation, Left Ventricular Ejection Fraction (LVEF) measurement by echocardiography at baseline and every 03 monthly for first year Serum samples for TNI were obtained immediately after chemotherapy and after 24 hrs Results: A total of 82 patients (all females) were included in the study Median age was 47 (range 30–64) years Anthracycline mediated cardiotoxicity occurred in 6 patients (7%) and was more frequent in patients with TNI elevation ( p <0001) Five patients (83%) recovered from cardiotoxicity At multivariate analysis, TNI elevation was the only independent predictor of cardiotoxicity (95% CI 00007879 to 02821) and of lack of LVEF recovery (95% CI 0002484 to 1680) Conclusion: Measurements of Trop I levels after Anthracyclines can be useful in detecting early cardiotoxicity and tailoring further therapy Keywords: Anthracyclines; Cardiotoxicity; Breast cancer; Troponin I; Left ventricular dysfunction
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cardiotoxicity of Anthracyclines.
TL;DR: The role of biomarkers, in particular troponins, in identifying subclinical cardiotoxicity and its therapy with angiotensin-converting enzyme inhibitors to prevent LVEF reduction is a recognized and effective strategy.
The Role of Biomarkers in Cardio-Oncology.
TL;DR: The evidence base behind the use of biomarkers for the detection of cardiotoxicity is discussed, including microRNAs, genome-wide association studies and proteomics are being studied as novel markers of cardiovascular injury or inflammation.
The breast cancer patient in the cardioncology unit
TL;DR: In this review, the advantages of a cardioncology approach in terms of risk stratification, monitoring for early diagnosis, prevention, and early treatment of cardiotoxicity are discussed.
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
TL;DR: In this paper , the authors present the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology, including cardiac troponin (cTn) and natriuretic peptides (NPs).
Cardiovascular toxicity of breast cancer treatment: an update.
TL;DR: In this paper, a literature review is presented to analyze the incidence and the underlying mechanisms of cardiovascular toxicity caused by agents approved for breast cancer, as well as to describe ways of monitoring and treating the cardiotoxic effects in breast cancer patients.
10
References
Risk factors for doxorubicin-induced congestive heart failure.
TL;DR: There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
2.4K
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
TL;DR: Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug, which is reflected in the incidence in the broader clinical oncology setting.
2.1K
Doxorubicin-Induced Cardiomyopathy
TL;DR: The tumors most commonly responding to doxorubicin when it is given as a single agent or in combination with other antitumor agents include breast and esophageal carcinomas; osteosarcoma, Kaposi's sarcoma and soft-tissue sarcomas; and Hodgkin's and non-Hodgkin's lymphomas.
1.8K
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
Daniela Cardinale,Alessandro Colombo,Maria T. Sandri,Giuseppina Lamantia,Nicola Colombo,Maurizio Civelli,Giovanni Martinelli,Fabrizio Veglia,Cesare Fiorentini,Carlo M. Cipolla +9 more
TL;DR: In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.
1K
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
Edward T.H. Yeh,Ann T. Tong,Daniel J. Lenihan,S. Wamique Yusuf,Joseph Swafford,Christopher J. Champion,Jean-Bernard Durand,H. R. Gibbs,Alireza Atef Zafarmand,Michael S. Ewer +9 more
TL;DR: In this article, the authors reviewed commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity and developed management plans, as well as strategies to reduce cardiotoxic effects.
888
Related Papers (5)
Heloisa Sawaya,Igal A. Sebag,Juan Carlos Plana,James L. Januzzi,Bonnie Ky,Bonnie Ky,Timothy C. Tan,Victor Cohen,Jose Banchs,Joseph R. Carver,Joseph R. Carver,Susan E. Wiegers,Susan E. Wiegers,Randolph P. Martin,Michael H. Picard,Robert E. Gerszten,Elkan F. Halpern,Jonathan J. Passeri,Irene Kuter,Marielle Scherrer-Crosbie +19 more